Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

David J Kuter, MD, DPhil, Mathias J Rummel, MD, PhD, Ralph Vincent Boccia, MD, B. Gail Macik, MD, Ingrid Pabinger, Dominik L.D. Selleslag, MD, Francesco Rodeghiero, Beng H Chong, MBBS, PhD, H. Müller-Beiβenhirtz, Lara Gehl, Xuena Wang, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 679.

https://doi.org/10.1182/blood.V114.22.679.679

Published: 2009

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ravi Patel, MD, Chien-Shing Chen, MD, Ralph Vincent Boccia, MD, Donald Colbourn, MD, Honghao (Hank) Yang, MD, PhD, Varun Gupta, MD, George F. Geils, Jr., MD, Youram Nassir, MD, Jacqueline Hilger, MS, Regina A. Swift

Blood (2009) 114 (22): 4936.

https://doi.org/10.1182/blood.V114.22.4936.4936

Published: 2009

Journal Articles

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

James R. Berenson, MD, Ralph Vincent Boccia, MD, Asad Bashey, MD PhD, Alexandra M. Levine, MD, Omer N. Koc, MD, Jennifer A. Callahan, Andrew P. Mazar, PhD, Steven D. Reich, MD

Blood (2006) 108 (11): 2593.

https://doi.org/10.1182/blood.V108.11.2593.2593

Published: 2006

Journal Articles

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Christine Chen, MD, Donna E. Reece, MD, David Siegel, MD, Ruben Niesvizky, MD, Ralph Vincent Boccia, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, David Irwin, MD, Jonathan Polikoff, MD, Shaji Kumar, MD, Richard A. Gams, MD, Laurie Kenvin, RN,BS, Dale McElveen, MBA, Angela Hu, MS, Dennis Pietronigro, PhD, Robert D. Knight, MD, Jerome B. Zeldis, MD,PhD

Blood (2006) 108 (11): 3556.

https://doi.org/10.1182/blood.V108.11.3556.3556

Published: 2006

Journal Articles

Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia.

Ralph Vincent Boccia, Peter T. Silberstein, Simon Tchekmedyian, Dianne Tomita, Greg Rossi, Greg Otterson

Blood (2005) 106 (11): 3767.

https://doi.org/10.1182/blood.V106.11.3767.3767

Published: 2005

Journal Articles

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia.

Ralph Vincent Boccia, Delong Liu, Peter Silberstein, Simon Tchekmedyian, Dianne Tomita, Greg Rossi, Greg Otterson

Blood (2004) 104 (11): 5310.

https://doi.org/10.1182/blood.V104.11.5310.5310

Published: 2004

NARROW

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia.

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia.

Email alerts

ASH Publications

American Society of Hematology

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia.

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only